



Canine acute pancreatitis:

Diagnosis and management

Fabio Procoli

DVM, MVetMed, DACVIM, DECVIM-CA, MRCVS






Definitions

Acute pancreatitis (AP)


Sterile suppurative inflammation Necrosis

Reversible



Chronic pancreatitis (CP)

Lymphoplasmacellular inflammation Fibrosis Parenchymal atrophy Irreversible



Prevalence unknown

AP historically more common than CP

Newman et al, 2004

73 pancreata from dogs deceased for many reasons

60% had evidence of pancreatitis

51% suppurative inflammation

49% necrosis

72% lymphocytic inflammation

60% fibrosis

Alternative classification

Based on duration/onset and severity of clinical signs

Pancreatic lipase increase

Severity


Duration

Diagnostic imaging

Clinical implications


AP more severe – higher morbidity

Higher risk of local and systemic complications – higher mortality



CP subtle – lower morbidity
Less common systemic complications –

rare mortality




Pathophysiology

Premature and inappropriate activation of pancreatic enzymes within acinar cells resulting in self-digestion

Apical block

Co-localization of lysosomal proteases and zymogens

Ischemia/hypotension
Oxidative stress
Intra-acinar pH alteration
Intracellular Ca2+ release
Biliary/pancreatic reflux



Forman MA, Steiner JM, Armstrong PJ, et al. JVIM. 2021; 35: 703-

Necrosis and death of acinar cells


Release of inflammatory mediators and chemotaxis

Influx of PLMNs

Increased capillary permeability

Paracellular barrier loss

Extension of the inflammatory process



Forman MA, Steiner JM, Armstrong PJ, et al. JVIM. 2021; 35: 703–723.

Complications

Local

Steatitis/peritonitis/duodenitis

Extrahepatic biliary obstruction (EHBO)

Formation of abscess or cysts or pseudocysts

Systemic

SIRS, AKI, ALI, CID MODS

Multicenter Study > J Vet Emerg Crit Care (San Antonio). 2019 May;29(3):264-268. doi: 10.1111/vec.12840. Epub 2019 Apr 29.

Multicenter investigation of hemostatic dysfunction in 15 dogs with acute pancreatitis

Lindsey Nielsen ¹, Jennifer Holm ¹, Elizabeth Rozanski ², Dawn Meola ², Lori Lyn Price ³, Armelle de Laforcade ²

RESEARCH ARTICLE

Open Access

Pulmonary complications in dogs with acute presentation of pancreatitis



Eleonora Gori, Alessio Pierini o, Gianila Ceccherini, Simonetta Citi, Tommaso Mannucci, Ilaria Lippi and Veronica Marchetti

Acute pancreatitis and acute kidney injury in dogs

E. Gori, I. Lippi, G. Guidi, F. Perondi, A. Pierini 🙎 🖂 , V. Marchetti

Cardiovascular abnormalities in dogs with acute pancreatitis

Harry Cridge 1 Daniel K. L

Daniel K. Langlois 1 | Jörg M. Steiner 2 |

Robert A. Sanders 1 0


From acute-to-chronic

Chronic low-grade inflammation Stellate cell activation (PSC) Fibrosis

Complications

Diabetes mellitus

EPI



Chronic pancreatitis in dogs: A retrospective study of clinical, clinicopathological, and histopathological findings in 61 cases

Brier M. Bostrom ^{a,1}, Panagiotis G. Xenoulis ^a, Shelley J. Newman ^b, Roy R. Pool ^c, Geoffrey T. Fosgate ^d, Jörg M. Steiner ^{a,*}

Ante-mortem diagnosis

Multimodal

Signalment

Medical history

Clinical and generic laboratory findings

Pancreatic lipases

Diagnostic imaging

Cytology

Histology?



Breed-associated risk





Characterization of chronic pancreatitis in English Cocker Spaniels

P J Watson ¹, A Roulois, T Scase, A Holloway, M E Herrtage









Hyperlipidaemia

Genetic predisposition

Oxidative damage
Hyperviscosity and ischaemia







J Vet Intern Mea 2011;25:20-25

Serum Triglyceride Concentrations in Miniature Schnauzers with and without a History of Probable Pancreatitis

Dietary indiscretion

Relative risk (odds ratio, OR)

Ingestion of table scraps - OR 2.2x Unusual food ingestion - OR 6.1x Garbage ingestion - OR 13.1x



Associations between dietary factors and pancreatitis in dogs

Kristina Y. Lem, DVM, MS; Geoffrey T. Fosgate, DVM, PhD, DACVPM; Bo Norby, C Med Vet, MPVM, PhD; Jörg M. Steiner, med vet, Dr med vet, PhD, DACVIM

Clinical presentation



AP

Vomiting 90%

Weakness 79%

Abdominal pain 58%

Dehydration 46%

Diarrhoea 33%

Fever 32%

Jaundice 26%

Haematemesis 10%

Clinical, clinicopathologic, radiographic, and ultrasonographic abnormalities in dogs with fatal acute pancreatitis: 70 cases (1986–1995)

Mild forms /early stage

Subtle

Nausea

Hyporexia

Weight loss



Chronic pancreatitis in dogs: A retrospective study of clinical, clinicopathological, and histopathological findings in 61 cases

Brier M. Bostrom a,1 , Panagiotis G. Xenoulis a , Shelley J. Newman b , Roy R. Pool c , Geoffrey T. Fosgate d , Jörg M. Steiner a,*



Clinical pathology

CBC

Neutrophilia +/- left shift – rarely neutropenia Thrombocytopenia Anaemia – mild, non regenerative



Serum biochem

Increased liver enzymes
Hyperbilirubinaemia
Hyperlipidaemia
Hypoalbuminaemia
Pre-renal or renal azotemia
Electrolytes inbalance

Clinical, clinicopathologic, radiographic, and ultrasonographic abnormalities in dogs with fatal acute pancreatitis: 70 cases (1986–1995)

Rebecka S. Hess, DVM; H. Mark Saunders, VMD, MS; Thomas J. Van Winkle, VMD; Frances S. Shofer, PhD; Robert J. Washabau, VMD, PhD

J Vet Intern Med 2016;30:116-122


Clinical Utility of Diagnostic Laboratory Tests in Dogs with Acute Pancreatitis: A Retrospective Investigation in a Primary Care Hospital

M. Yuki, T. Hirano, N. Nagata, S. Kitano, K. Imataka, R. Tawada, R. Shimada, and M. Ogawa

Serum C reactive protein

Increased in 90% of cases of AP in dogs

Decrease associated with survival to discharge



S: Group S N: Group N

Holm, J.L. et al (2004). JVEEC:14, 183-186.

Haemostasis

Nielsen et al, 2019

38% thrombosis 55% portal vein thrombosis

AP included by ACVECC consensus as major indication for institution of prophylactic anti-platelet and anticoagulant therapy

<u>J Vet Emerg Crit Care (San Antonio).</u> 2019 May;29(3):264-268. doi: 10.1111/vec.12840. Epub 2019 Apr 29.

Multicenter investigation of hemostatic dysfunction in 15 dogs with acute pancreatitis.


Nielsen L¹, Holm J¹, Rozanski E², Meola D², Price LL^{3,4}, de Laforcade A².

Pancreatic «specific» tests

Immunological methods

cPLI (Spec cPL®)
fPLI (Spec fPL®)
SNAP c/f PL®

Catalytic methods
Lipase DGGR



Pancreatic lipase immunoreactivity (PLI)

Spec cPLTM (& Spec fPLTM)

Considered the most sensitive and specific marker for the diagnosis of pancreatitis ELISA method (monoclonal antibodies)

Not affected by jaundice, hemolysis, lipemia

Analytically validated in dogs and cats





Article

Development and analytic validation of an enzyme-linked immunosorbent assay for the measurement of canine pancreatic lipase immunoreactivity in serum

Development and analytical validation of a radioimmunoassay for the measurement of feline pancreatic lipase immunoreactivity in serum

Interpretation

0-200 ug/L pancreatitis unlikely 200-400 ug/L pancreatitis possible > 400 ug/L pancreatitis probable

	Cut-off 200	400
Sensitivity	43-94%	21-90 %
	66-95%	74-100%
Specificity		•

Clinical performance - dog


McCord et al, 2012

84 dogs

Spec cPL < 200 mcg/L tends to rule out pancreatitis in low-risk population

Up to 20% of patients deemed not to have pancreatitis had >400 mcg/L

Absence of linearity between disease increase and severity or prognosis




J Vet Intern Med 2012:26:888-896

A Multi-Institutional Study Evaluating the Diagnostic Utility of the Spec cPL^{TM} and $SNAP \otimes cPL^{TM}$ in Clinical Acute Pancreatitis in 84 Dogs

K. McCord, P.S. Morley, J. Armstrong, K. Simpson, M. Rishniw, M.A. Forman, D. Biller, N. Parnell, K. Arnell, S. Hill, S. Avgeris, H. Gittelman, M. Moore, M. Hitt, G. Oswald, S. Marks, D. Burney, and D. Twedt

Lateral flow immunoassay – SNAP c/fPLTM





94.0% - 97.4% agreement with Spec cPL

J Vet Intern Med 2012;26:888-896

A Multi-Institutional Study Evaluating the Diagnostic Utility of the Spec cPL^{TM} and $SNAP @ cPL^{TM}$ in Clinical Acute Pancreatitis in 84 Dogs

K. McCord, P.S. Morley, J. Armstrong, K. Simpson, M. Rishniw, M.A. Forman, D. Biller, N. Parnell, K. Arnell, S. Hill, S. Avgeris, H. Gittelman, M. Moore, M. Hitt, G. Oswald, S. Marks, D. Burney, and D. Twedt

97.5% agreement for negative/normal 90% for positive results

DGGR lipase

1,2 dilauryl-rac-glycero-3 glutaric acid ester

Substrate hydrolysed by pancreatic lipase (but not only)

Kook et al, 2014

Good agreement with Spec cPL when > 216 U/L Sensitivity and specificity similar to Spec cPL

Agreement ((valore	k, 95% CI)

	Spec cPL >200 μ g/L	Spec cPL >400 µg/L
Lipase >108 U/L	0.795 (CI, 0.69–0.9)	0.551 (CI, 0.43–0.67)
Lipase >162 U/L	0.753 (CI, 0.64–0.86)	0.774 (CI, 0.67–0.88)
Lipase >216 U/L	0.699 (CI, 0.58–0.82)	0.803 (CI, 0.71–0.9)

J Vet Intern Med 2014;28:863-870

Agreement of Serum Spec cPL with the 1,2-o-Dilauryl-Rac-Glycero Glutaric Acid-(6'-methylresorufin) Ester (DGGR) Lipase Assay and with Pancreatic Ultrasonography in Dogs with Suspected Pancreatitis

P.H. Kook, N. Kohler, S. Hartnack, B. Riond, and C.E. Reusch

DGGR lipase - limitations

Reflects activity of other isoenzymes (hepatic, gastric)

Increases with reduced GFR (reduced clearance)

Increases with hyperadrenocorticism and glucocorticoid therapy (markedly)

High variability between assays on the market

Can Vet J. 2020 Jul;61(7):743-748.

Evaluation of 1,2-o-dilauryl-rac-glycero-3-glutaric acid-(6'-methylresorufin) ester lipase concentrations in cats with kidney disease and with normal SNAP fPL

```
Anne-Sophie Bua <sup>1</sup>, Carolyn Grimes <sup>1</sup>, Guy Beauchamp <sup>1</sup>, Marilyn E Dunn <sup>1</sup>
```

> J Vet Intern Med. 2020 Nov;34(6):2330-2336. doi: 10.1111/jvim.15946. Epub 2020 Nov 4.


Effect of prednisolone therapy on serum levels of 1,2-O-dilauryl-rac-glycero glutaric acid-(6'-methylresorufin) ester lipase in dogs

```
Beatriz Mendoza <sup>1</sup>, Maria Joana Dias <sup>1</sup>, Telmo Nunes <sup>1</sup>,
Maria Alexandra Basso <sup>1</sup>, Juan Hernandez <sup>2</sup>, Rodolfo Oliveira Leal <sup>1</sup> <sup>3</sup>
```

> J Vet Diagn Invest. 2021 Sep;33(5):817-824. doi: 10.1177/10406387211021345. Epub 2021 Jun 2.

Evaluation of 1,2-O-dilauryl-rac-glycero glutaric acid-(6'-methylresorufin) ester (DGGR) and 1,2-diglyceride lipase assays in dogs with naturally occurring hypercortisolism


```
Guido Linari <sup>1</sup>, Francesco Dondi <sup>1</sup>, Sofia Segatore <sup>1</sup>, Kateryna Vasylyeva <sup>1</sup>, Nikolina Linta <sup>1</sup>, Marco Pietra <sup>1</sup>, Rodolfo O Leal <sup>2</sup>, Federico Fracassi <sup>1</sup>
```



> J Vet Diagn Invest. 2021 Sep;33(5):817-824. doi: 10.1177/10406387211021345. Epub 2021 Jun 2.

Evaluation of 1,2-O-dilauryl-rac-glycero glutaric acid-(6'-methylresorufin) ester (DGGR) and 1,2-diglyceride lipase assays in dogs with naturally occurring hypercortisolism

Guido Linari ¹, Francesco Dondi ¹, Sofia Segatore ¹, Kateryna Vasylyeva ¹, Nikolina Linta ¹, Marco Pietra ¹, Rodolfo O Leal ², Federico Fracassi ¹



Received: 28 July 2020 Accepted: 13 October 2020

DOI: 10.1111/jvim.15946

STANDARD ARTICLE




Effect of prednisolone therapy on serum levels of 1,2-O-dilauryl-*rac*-glycero glutaric acid-(6'-methylresorufin) ester lipase in dogs

Beatriz Mendoza¹ | Maria Joana Dias¹ | Telmo Nunes¹ |
Maria Alexandra Basso¹ | Juan Hernandez² | Rodolfo Oliveira Leal^{1,3} |

Introducing the Catalyst® Pancreatic Lipase Test







+ Accurate and specific quantitative results that align with the IDEXX Reference Laboratories Spec cPL® and Spec fPL® tests.



+ One test validated for both dogs and cats.



+ Flexible testing that allows running alone or with additional chemistry tests in a single run using one sample.



+ Load-and-go workflow that provides results in real time.



+ Integrated results with other diagnostic testing on VetConnect® PLUS.





Strong agreement between Catalyst® Pancreatic Lipase Test and Spec® cPL™

		Ove	rall agreement	84.8%	
			Spec cPL		
5			≤ 200 µg/L	201–399 μg/L	≥ 400 µg/L
	Catalyst PL	≤ 200 U/L	51.4%	6.2%	0.0%
		201–399 U/L	1.8%	13.0%	2.8%
		≥ 400 U/L	0.0%	4.5%	20.4%



		Spec cPL			
		≤ 200 µg/L	201–399 μg/L	≥ 400 µg/L	
0-1-11	≤ 200 U/L	89.3%	10.7%	0.0%	100%
Catalyst PL	201–399 U/L	10.4%	73.9%	15.7%	100%
	≥ 400 U/L	0.0%	17.9%	82.1%	100%



Monitoring over time

Cueni et al, 2023

39 dogs hospitalised with AP


Spec cPL e DGGR lipase normalised within 2 days in 50% cases


sCRP remained increased in majority of dogs at day 3




Progression of lipase activity and pancreatic lipase immunoreactivity in dogs hospitalized for acute pancreatitis and correlation with clinical features

Claudia Cueni | Natalie Hofer-Inteeworn | Claudia Kümmerle-Fraune
Claudia Müller | Peter Hendrik Kook







Abdominal ultrasound

DI modality of choice

Dogs < 25 kg bw – once analgesic control achieved



Variables of interest

Pancreatic echogenicity and volume


Echogenicity of peripancreatic fat

Pancreatic-duodenal LN

Duodenal corrugation

Pancreatic and biliary duct

Abdominal effusion



Performance variabile (AP > CP)

Sensitivity 43-89%

Specificity 43 -92%

Abdominal ultrasound – considerations

Contraindicated if acute abdominal pain not controlled

Operator-dependant

Findings dependent on severity and duration of disease

Lag-phase 1-4 gg vs clinical signs and lipases (Gori et al, 2021)

Concordance with Spec fPL and DGGR lipase variable

Ultrasonographic remission slow vs clinical signs

Performance variabile (AP > CP)

Sensitivity 43-89%

Specificity 43 -92%

> J Am Vet Med Assoc. 2021 Sep 15;259(6):631-636. doi: 10.2460/javma.259.6.631.

Evaluation of diagnostic and prognostic usefulness of abdominal ultrasonography in dogs with clinical signs of acute pancreatitis

Grace

Border collie - 10 yrs old FN

Acute abdomen + severe vomiting after dietary indiscretion BCS 7/9

sCRP 13.9 mg/L Spec cPL > 2,000 ug/L







Grace – 1 month later

No clinical signs sCRP < 0.01 mg/L Spec cPL 60 ug/L



Pancreatic histopathology

Needed for definitive diagnosis and classification

Limitations:

Invasive

Expensive

Need for multiple biopsies (multifocal/patchy pathology)

Equivocal significance of histological evidence in the absence of clinical symptoms

Little impact on treatment strategy

Brief Communications

J Vet Diagn Invest 18:115-118 (2006)


Cytology


Minimally invasive

Safe - complication rate 3% (*Crain et al 2014*)
Bleeding
Hypotension

Findings
Acinar epithelial degeneration
Neutrophils
Necrosis

CP often acellular





J Vet Diagn Invest 22:702-707 (2010)

Effect of pancreatic tissue sampling on serum pancreatic enzyme levels in clinically healthy dogs

Amy P. Cordner, P. Jane Armstrong, Shelley J. Newman, Roberto Novo, Leslie C. Sharkey, Carl Jessen (*emeritus*)







Understanding lipase assays in the diagnosis of pancreatitis in veterinary medicine

Sue Yee Lim, DVM, PhD1; Jörg M. Steiner, DVM, PhD, DACVIM, DECVIM1; Harry Cridge, MVB, MS, DACVIM, DECVIM2*

¹Gastrointestinal Laboratory, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX ²Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, MI

Proposed interpretive criteria:

Criteria for clinically probable acute pancreatitis:

- > cut-off value for pancreatic lipase concentration or activity
- ≥ 2 sonographic features of acute pancreatitis (or CTA evidence of acute pancreatitis).²

Criteria for clinically suspect acute pancreatitis:

- > cut-off value for pancreatic lipase concentration or activity + < 2 sonographic features of acute pancreatitis.²
- Or equivocal pancreatic lipase concentration or activity + ≥ 2 sonographic features of acute pancreatitis
- Clinical action: repeat imaging &/or pancreatic lipase measurement over time is indicated. Sonographic
 features of acute pancreatitis can lag behind elevated pancreatic lipase increase. Consider pancreatic fine
 needle aspirate.

Unlikely to be acute pancreatitis:


- Within reference interval pancreatic lipase concentration or activity
- < 2 sonographic features of acute pancreatitis

Figure 3—Decision tree for interpretation of lipase assays in the context of a clinical patient.

Managing acute pancreatitis in dogs



Management



Analgesia

Uncontrolled visceral pain can

Reduce appetite and induce malnutrition

Increase stress cardiovascular stress

Increase peripheral O₂ consumption

Activate inflammatory cascade (neurogenic)

Reduce gastrointestinal motility

Clinical signs indicative of pain

Tachycardia

Hypertension

Tachypnea

Lethargy or agitation

Hyperthermia

Anorexia

Individualised approach

Table 3. An outline of the levels of pain that are potentially manifested in dogs with acute pancreatitis, as adapted from the Glasgow Composite Pain Scale and recommended analgesia

Anticipated levels	of pain associated with acute pancreatitis	Potential analgesic combination	Level of evidence
Mild	Quiet but responsive to surroundings; unsettled; looks around when abdomen is palpated	Buprenorphine or methadone (or other full µ-agonist) at high-end of dosage and frequency, reducing down once pain well controlled	D (dogs)
Moderate	Decreased response to surroundings or stimuli; slow or reluctant to move; restless; stretching of abdomen, look- ing around at abdomen; flinches on abdominal palpation	Buprenorphine or methadone (or other full µ-agonist) at high-end of dosage and frequency, PLUS Lidocaine and Ketamine infusion. Once pain well controlled, reduce ketamine infusion first until 5 µg/kg/minute then stop, then reduce lidocaine until 25 µg/kg/minute then stop, then reduce dosage and frequency of opioid.	D (dogs)
Severe to excruciating	Non-responsive to stimuli; refuses to move or get up; screams, cries or snaps when tries to get up or abdomen palpated	Epidural morphine or fentanyl infusion PLUS lidocaine/ketamine infusion. Once pain well controlled, change epidural to opioid as above, then reduce ketamine infusion first until 5 μg/kg/minute, stop and then reduce lidocaine until 25 μg/kg/minute, then stop, and then reduce dosage and frequency of opioid.	D (dogs)
Unexpected exac- erbation of pain		Assess for pancreatic fluid collection and aspirate via ultrasound guidance	C (dogs)
Adjunctive management	Added with any level of pain	Gabapentin	D (dogs)
	Added if opioids associated with	Methylnaltrexone	D (dogs)
	decreased gastrointestinal motility		C (humans)

Fluid therapy

Correct dehydration and/or hypovolaemia

Re-establish pancreatic perfusion

Avoid ischemia and thrombosis

Correct electrolytes inbalance

Type and rate of fluids based on patient evaluation

MMs, CRT, lactate, SIBP





Individualised approach

For dehydrated patients:

Isotonic solutions
Maintenance + % dehydration + ongoing losses
(40-60ml/kg/h) + (in 6-24 hours) + (estimate volume of V/D)

For hypovolemic/«shocky» patients

Isotonic solutions (rarely hypertonic or natural colloids) EV boluses of 10 ml/kg (5ml/kg cats) over 15 minutes with reevaluation

In case of AKI

Ins and outs: fluid going in match fluids going out (insensible losses + volume of urine, V/D)

Nutritional support - early

Consequences of prolonged fasting

Intestinal villi atrophy/ apoptosis of enterocytes

Decrease in goblet and deep crypt cells Reduced transport of glutamine and arginine

Increased intestinal permeability
Risk of bacterial translocation

Mansfield et al, 2008

Lack of return to enteral nutrition for ≥3 days associated with negative outcome



Nutritional management of acute pancreatitis in dogs and cats

Kristine B. Jensen, DVM, MVetMed, MRCVS and Daniel L. Chan, DVM, DACVECC, DACVN, MRCVS

> J Am Vet Med Assoc. 2008 Sep 15;233(6):936-44. doi: 10.2460/javma.233.6.936.

Development of a clinical severity index for dogs with acute pancreatitis

Caroline S Mansfield 1, Fleur E James, Ian D Robertson

Individualised management

Feeding tubes

Nasoesophageal or nasogastric vs esophagostomic

Jejunostomy in case of uncontrollable vomiting or severe
ileus

Which diet?

Highly digestible

Energy dense

Low-fat in case of hyperlipidaemia

Antibiotics

No scientific evidence to support systemic use

Can cause

Dysbiosis

GI toxicity


Antibiotic resistance


Consider only in case of suspected SEPSIS, aspiration pneumonia, bacterial translocation


Use antibiotics that are effective against enterobacteria


Amoxycillin + clavulanate or cephalexin 20mg/kg IV q8 hours















PAPER

Comparison of initial treatment with and without corticosteroids for suspected acute pancreatitis in dogs

Surgery

In case of complete EHBO
Cholecystoduodenostomy
Stenting

Necrotising pancreatitis and peritonitis Peritoneal lavage

Abscesses

Omentalisation

High mortality rate 50-86%



Treatment for pancreatic abscesses via omentalization with abdominal closure versus open peritoneal drainage in dogs: 15 cases (1994–2004)

Matthew D. Johnson, DVM, and F. A. Mann, DVM, MS, DACVS, DACVECC

> J Am Anim Hosp Assoc. 2008 Jul-Aug;44(4):171-9. doi: 10.5326/0440171.

Pancreatic abscess in 36 dogs: a retrospective analysis of prognostic indicators

Jonathan R Anderson ¹, Karen K Cornell, Nolie K Parnell, S Kathleen Salisbury

DOI: 10.1111/jvim.16411

STANDARD ARTICLE



Medical and surgical management of pancreatic fluid accumulations in dogs: A retrospective study of 15 cases

Charles T. Talbot¹ | Ring Cheung² | Emma J. Holmes³ | Simon D. Cook¹





FIGURE 1 Management and survival of medically and surgically managed cases with pancreatic fluid accumulation

Fuzapladib (Panoquell®- CA1)

Leukocyte function-associated 1 (LFA-1) antagonist

LFA-1 expressed on neutrophils
Binds ICAM-1 expressed on endothelium




Steiner et al, JVIM 2023

61 dogs with presumptive AP

Safety study followed by efficacy study (n35)

16n Fuza 0.4 mg/kg IV for 3 days vs 19n placebo





Steiner JM, Lainesse C, Noshiro Y, et al. J Vet Intern Med 2023; 37(6): 2084-2092.

Prognosis

Mortality 27-58%

Putative negative prognostic markers

CRP

Thrombocytopenia

Dyspnea

Ascites

SIRS coagulopathy, hypocalcaemia, azotemia

UPC ratio >2

Mansfield et al. 2008
Kathrani et al. 2009
Papa et al. 2011
Stockhaus et al. 2013
Tvarijonaviciute et al. 2014
Marchetti et al. 2017
Fabres et al. 2019
Kuzi et al. 2019

Fabres et al. 2019

Gori et al. 2019

CRP vs Spec cPL – prediction of survival

Oberholtzer et al, 2024 - 503 dogs with cPLI and CRP

143 (27%) hospitalized

49 (9.7%) deceased or euthanised

Spec cPL hospitalized vs discharged dogs overlapping

Median sCRP in hospitalised (36.1 vs 9.9 mg/L) vs deceased (37.2 vs 9.9 mg/L)

Dogs with baseline CRP > 10 mg/L 5x risk of death

JAVMA



Prognostic value of C-reactive protein in dogs with elevated serum pancreatic lipase immunoreactivity concentrations



Fabio.Procoli@anicura.it IG @fabioprothevet



Thank you very much for the attention!



Questions?

